Completed PHASE4 INTERVENTIONAL 1-arm NCT01050478

IMPACT: A Study to Explore the Efficacy and Safety of Paliperidone ER in Patients With Acute Agitation

Open-label, Single Arm, Interventional Study to Explore the Efficacy and Safety of Paliperidone ER in the Management of Patients With Acute Agitation and/or Aggression

Sponsor: Janssen Cilag N.V./S.A.

Conditions Acute Disease Psychomotor Agitation

Interventions Benzodiazepine Paliperidone ER

Updated 6 times since 2017 Last updated: Feb 8, 2016 Started: Mar 31, 2010 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Acute Disease and Psychomotor Agitation, this trial is completed. The trial is conducted by Janssen Cilag N.V./S.A. and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janssen Cilag N.V./S.A.

Data source: Janssen Cilag N.V./S.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bruges, Belgium , Brussels, Belgium , Dave, Belgium , Diest, Belgium , Ghent, Belgium , Henri-Chapelle, Belgium , Heusden, Belgium , Kortrijk, Belgium , La Louvière, Belgium , Liège, Belgium and 4 more locations